Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
暂无分享,去创建一个
L. Rimassa | N. Personeni | T. Pressiani | Yi‐Hsiang Huang | T. Marron | D. Bettinger | D. Pinato | T. Jun | David Szafron | A. Saeed | C. Ang | A. Kaseb | Y. Abugabal | U. Khan | F. Benevento | Yinghong Wang | M. Muzaffar | Petros Fessas | Chieh-Ju Lee | S. Paul | H. Hildebrand | M. Navaid | Anushi Bulumulle | Sirish Dharmapuri | N. Nimkar | Bo Yu | Abdul Rafeh Naqash
[1] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[2] Ching Ngar Wong,et al. Immune-based therapies for hepatocellular carcinoma , 2020, Oncogene.
[3] K. Lan,et al. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma , 2020, Cancers.
[4] M. Kudo,et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Kudo,et al. A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results , 2019, Annals of Oncology.
[6] M. Kudo,et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) , 2019, Annals of Oncology.
[7] S. Behr,et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series , 2019, Cancer.
[8] M. Kudo,et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. , 2019, Journal of Clinical Oncology.
[9] J. Trojan,et al. Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort , 2019, Alimentary pharmacology & therapeutics.
[10] M. Kudo. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond , 2019, World journal of gastroenterology.
[11] M. Kudo,et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[12] M. Kudo,et al. Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. , 2019, Journal of Clinical Oncology.
[13] P. Schirmacher,et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Markus Peck-Radosavljevic,et al. Review article: systemic treatment of hepatocellular carcinoma , 2018, Alimentary pharmacology & therapeutics.
[15] Gisela Schwab,et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.
[16] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[17] B. Guo,et al. Mechanisms of resistance to chemotherapy and radiotherapy in hepatocellular carcinoma , 2018, Translational Cancer Research.
[18] G. Freeman,et al. Role of PD-1 during effector CD8 T cell differentiation , 2018, Proceedings of the National Academy of Sciences.
[19] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[20] Rajdeep Chowdhury,et al. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight , 2018, Cancer cell international.
[21] C. la Vecchia,et al. Global trends and predictions in hepatocellular carcinoma mortality. , 2017, Journal of hepatology.
[22] M. Kudo,et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.
[23] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[24] Masatoshi Kudo,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[25] David Victor,et al. Hepatocellular carcinoma: a review , 2016, Journal of hepatocellular carcinoma.
[26] Ender Gunes Yegin,et al. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. , 2016, Hepatobiliary & pancreatic diseases international : HBPD INT.
[27] A. Ribas,et al. Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.
[28] X. Wang,et al. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches , 2015, Gut.
[29] M. Álvarez-Mon,et al. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. , 2014, Journal of hepatology.
[30] T. Greten,et al. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions , 2014, Hepatology.
[31] R. Labianca,et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. , 2013 .
[32] P. Tien,et al. PD‐1 and PD‐L1 upregulation promotes CD8+ T‐cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients , 2011, International journal of cancer.
[33] C. Porta,et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] S. Qiu,et al. Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.
[35] M. Thomas. Molecular targeted therapy for hepatocellular carcinoma , 2009, Journal of Gastroenterology.
[36] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[37] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[38] Jia Fan,et al. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. , 2018, Gastroenterology.